Balance Sheet Components

6 Months Ended

Jun. 30, 2025

Balance Sheet Related Disclosures [Abstract]

Goodwill

Goodwill was $773.3 million and $745.8 million as of June 30, 2025 and December 31, 2024, respectively. The changes in the carrying amounts of goodwill during the three and six months ended June 30, 2025 were due to foreign currency translation. The Company has not recorded any impairment related to goodwill.

Intangible Assets, Net

Intangible assets include finite-lived product technology, customer relationships, licenses and trade names and indefinite-lived in-process research and development. Intangible assets consisted of the following (in thousands of dollars):


	June 30, 2025						December 31, 2024						Weighted Average Remaining Amortization Period (Years)
	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Percepta product technology	$	16,000	$	(10,933)	$	5,067	$	16,000	$	(10,400)	$	5,600	5
Prosigna product technology	4,120		(1,534)		2,586		4,120		(1,396)		2,724		9
Decipher product technology	97,300		(38,815)		58,485		90,000		(34,234)		55,766		7
Decipher trade names	4,000		(3,443)		557		4,000		(3,043)		957		1
C2i developed technology	25,300		(2,389)		22,911		25,300		(1,546)		23,754		14
Total finite-lived intangibles	146,720		(57,114)		89,606		139,420		(50,619)		88,801		8.5
In-process research and development	6,200		—		6,200		13,500		—		13,500
Total intangible assets	$	152,920	$	(57,114)	$	95,806	$	152,920	$	(50,619)	$	102,301

Acquisition-related intangibles are generally finite-lived and are carried at cost less accumulated amortization. Amortization of the finite-lived intangible assets is recognized on a straight-line basis over their estimated lives, which approximates the pattern in which the economic benefits of the intangible assets are expected to be realized.

Amortization expense of $3.3 million and $3.8 million was recognized for the three months ended June 30, 2025 and 2024, respectively, and an expense of $6.5 million and $7.4 million was recognized for the six months ended June 30, 2025 and 2024, respectively.

The estimated future aggregate amortization expense as of June 30, 2025 is as follows (in thousands of dollars):


Year Ending December 31,	Amounts
2025 remainder of year	$	6,657
2026	12,672
2027	12,515
2028	12,515
2029	12,515
Thereafter	32,732
Total	$	89,606

Supplies and Inventory

Supplies consisted of lab supplies and reagents to be used in the performance of testing services. Inventory related to finished and semi-finished goods used in the assembly of diagnostic kits related to product sales as well as raw materials consumed in the contract manufacturing process. As of June 30, 2025 and December 31, 2024, supplies and inventory consisted of the following (in thousands of dollars):


	June 30, 2025		December 31, 2024
Supplies	$	20,065	$	17,876
Inventory	4,955		3,874
Total supplies and inventory	$	25,020	$	21,750

Impairment of Assets

On July 16, 2025, the Marseille Commercial Court published a decision approving the divestiture of certain portions of the Company's French subsidiary, Veracyte SAS, to Helio Diagnostics SAS, effective August 1, 2025. The remaining assets will be managed by the judicial administrator until such time that the Marseille Commercial Court appoints a judicial liquidator to solely initiate and manage liquidation proceedings. Effective August 1, 2025, the Company no longer has the power to control the financial and operating policies of Veracyte SAS. The Company assessed the associated assets as of June 30, 2025 for impairment and determined that the value of the remaining assets of Veracyte SAS, including accounts receivable; supplies and inventory; right-of-use assets; property, plant, and equipment; and other receivables were not recoverable. As a result, the Company recorded a $20.5 million non-cash impairment charge during the three months ended June 30, 2025, as detailed in the impairment of assets row of the condensed consolidated statement of operations. See Note 11, Subsequent Events, for more information regarding Veracyte SAS.

Accrued Liabilities

Accrued liabilities consisted of the following (in thousands of dollars):


	June 30, 2025		December 31, 2024
Accrued compensation expenses	$	25,764	$	30,595
Accrued other	17,943		13,231
Total accrued liabilities	$	43,707	$	43,826